 |
 |
 |
| Search news stories |
Press Releases | |||
CellCentric’s Scientific Founder Awarded Royal MedalProf Azim Surani FRS CBE has been awarded the Royal Society’s Royal Medal for his pivotal contributions to the understanding of early mammalian development. Azim Surani, the Marshall-Walton Professor of Physiology at the Gurdon Institute, University of Cambridge, has received another major award for his pioneering research into mammalian developmental mechanisms.
Three Royal Medals are awarded annually by the Queen upon the recommendation o... | August 31, 2010 | ||
CellCentric Key Collaborator Awarded FRSProfessor Wolf Reik Head of the Laboratory of Developmental Genetics and Imprinting at the Babraham Institute has been elected to the Fellowship of the Royal Society. Professor Reik is a world leading authority in the field of epigenetics.
CellCentric has been working with Prof Reik since 2006. The company and his laboratory have ongoing collaborative research looking at the mechanisms of epigenetic reprogramming. Patents from his work have been filed and licensed to ... | May 24, 2010 | ||
CellCentric Receives Two Research Awards from the BBSRCGrant funding has been gained from the Biotechnology and Biological Sciences Research Council (BBSRC) to further CellCentric’s investigation of epigenetic control mechanisms and the identification of small molecule modulators, in collaboration with Professor Wolf Reik at the Babraham Institute.
CellCentric, the biotechnology company focused on epigenetics, has been awarded £433,000 of BBSRC ‘Stand-alone’ LINK funding to further its research on ... | May 11, 2010 | ||
CellCentric Licenses Novel Epigenetic Discovery Programme to TakedaFrom its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.
Under the terms of the new agreement, CellCentric will receive from Takeda Pharmaceutical Company Limited an upfront payment and pre-clinical and clinical milestones, in addition to royalties. Based on the royalties and milestones defined, the overall deal could be worth in excess of $200m... | February 23, 2010 | ||
CellCentric heads new collaboration with Sigma-Aldrich, The Automation Partnership and leading epigenetic researchersThe University of Cambridge, UCL (University College London), CellCentric, Sigma-Aldrich and The Automation Partnership embark on a collaboration to define markers of epigenetic reprogramming, supported by £1.1m from the UK Government’s Technology Strategy Board.
CAMBRIDGE, UK, 16th February 2010
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has led a consortium in winning a competi... | February 16, 2010 | ||
CellCentric epigenetic imprint erasure factor published in NatureNew data from Prof. Wolf Reik of the Babraham Institute, Cambridge, highlights the key role of the cytidine deaminase AID in DNA demethylation and the reprogramming of cells. CAMBRIDGE, UK, 25th January 2010
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has an ongoing research relationship with Prof. Wolf Reik at the Babraham Institute, Cambridge. New work from hi... [Read more] | January 25, 2010 | ||
CellCentric Cancer Target Review in Drug Discovery TodayCellCentric's Director of Exploratory Research, Nessa Carey and colleague Jonathan Best publish a review on epigenetics and oncology in Drug Discovery Today.
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has ties to over 30 leading research labs in epigenetics. The network involves a wide breadth of world leaders in molecular and developmental biology, disease mode... | January 6, 2010 | ||
CellCentric’s Innovative Business Model Highlighted in Trends in BiotechnologyCellCentric has a unique approach to harnessing innovation through a platform of multiple relationships with worldwide leaders in epigenetics. The strength of the company’s model and the value created to the multiple stakeholders involved, is reviewed in a new publication.
CAMBRIDGE, UK, 28th August 2009
| August 28, 2009 | ||
From Imprinting to the Epigenome in 25 years - CellCentric ConferenceHeritable information, separate from the DNA code, was first reported 25 years ago. Subsequent research is having a profound influence on the understanding of how cells work and how diseases can be treated.
CAMBRIDGE, UK, 2nd June 2009
| June 2, 2009 | ||
CellCentric Widens Drug Screening in ShanghaiCellCentric has expanded its agreement with Shanghai-based HD Biosciences to move epigenetic targets from screening into drug discovery
CAMBRIDGE, UK, 6th May 2009
| May 6, 2009 | ||
CellCentric Secures 25th Epigenetics Academic AgreementCellCentric’s discovery network represents the single strongest commercial discovery resource in epigenetics.
Knowledge assimilation in novel targets and cell fate control mechanisms has led to deals with Pfizer as well as Takeda.
CAMBRIDGE, UK, 21st April 2009
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has further expanded its network of... | Apr 21, 2009 | ||
CellCentric Expands its Leadership TeamNewly appointed President and CSO, David Knowles, and Director of Discovery Research, Neil Pegg will drive CellCentric’s epigenetic target programmes into lead optimisation and beyond.
CAMBRIDGE, UK, 4th February 2009
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, is expanding its leadership team further to capitalise on its multiple target and small molecule programmes. ... [Read more] | Feb 4, 2009 | ||
CellCentric Collaborates on Epigenetic Programme with TakedaNew agreement funds the further validation of a target identified by CellCentric, and gives Takeda an option to licence the discovery programme.
CAMBRIDGE, UK, 6th January 2009
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has signed an agreement with Takeda, the largest pharmaceutical company in Japan, that covers further validation of an epigenetic target. Early evidence suggests that the pro... | Jan 6, 2009 | ||
Archive Press Releases | |||
| CellCentric and Cancer Research Technology Collaborate on Epigenetic Discoveries. [Read more] | Nov 14, 2007 | ||
| CellCentric receives funding from Takeda Research Investment, Inc. [Read more] | Oct 2, 2007 | ||
| CellCentric signs IP agreement with Massachusetts General Hospital [Read more] | Jun 15, 2007 | ||
| Scientific Founder Wins Prestigious Rosenstiel Award [Read more] | May 15, 2007 | ||
| CellCentric expands its epigenetic discovery network [Read more] | Jan 7, 2007 | ||
| CellCentric raises £1.2m of venture capital [Read more] | Jul 18, 2006 | ||
| Drug discovery and commercial experience boost CellCentric team [Read more] | Jun 28, 2006 | ||
| CellCentric receives £1.15m DTI award [Read more] | May 4, 2006 | ||
| CellCentric announces the appointment of Dr Tim Fell as Chief Operating Officer (COO) [Read more] | Apr 5, 2006 | ||
| CellCentric collaborates with University College London's Wolfson Institute to accelerate its cancer drug discovery [Read more] | Nov 1, 2005 | ||
| CellCentric and Cancer Research Technology initiate co-development partnership [Read more] | Sep 26, 2005 | ||
| CellCentric receives new funding from NESTA to further its work in epigenetics and cancer [Read more] | Sep 5, 2005 | ||
| CellCentric receives new funding and links up with the Babraham Institute [Read more] | Apr 7, 2005 | ||